Trials / Completed
CompletedNCT00088036
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol is to evaluate the efficacy and safety of olanzapine compared with placebo in patients with Borderline Personality Disorder (BPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olanzapine |
Timeline
- Start date
- 2004-02-01
- Completion
- 2006-01-01
- First posted
- 2004-07-21
- Last updated
- 2006-07-24
Locations
15 sites across 5 countries: United States, Argentina, Poland, Romania, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00088036. Inclusion in this directory is not an endorsement.